BMS-856 is a novel and potent inhibition of 17beta-HSD3. It is usedful for endocrine therapy of prostate cancer (PCa) which relies on agents which disrupt the biosynthesis of testosterone in the testis and/or by direct antagonism of active hormone on the androgen receptor (AR) in non-gonadal target tissues of hormone action such as the prostate.

纯度：≥98%

CAS：863382-83-6